675 studies (9 from unattributed sources) on Tirzepatide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified. Read the full grey-market analysis →
| Manufacturer | Batches | Avg purity | |
|---|---|---|---|
| Bfflist Amo | 247 | 99.61% | View COA → |
| Sry Labs | 207 | 99.55% | View COA → |
| Shanghai Sigma Audley Ssa | 140 | 99.56% | View COA → |
| Hk Peptides | 133 | 99.76% | View COA → |
| Allen Biotechnology Co Abc | 124 | 99.66% | View COA → |
| Planet Peptide | 105 | 99.76% | View COA → |
| Zlz Peptide | 94 | 99.72% | View COA → |
| GYC | 93 | 99.73% | View COA → |
Recent certificates: #27962 (99.94%) · #28001 (99.52%) · #30760 (99.98%) · #31566 (99.96%) · #42192 (99.69%) · #42719 (99.95%)
Manufacturers with published third-party certificates of analysis for Tirzepatide. Open a vendor to see every batch we've verified.
Combining Tirzepatide with Ixekizumab significantly improved disease control in adults with psoriatic arthritis and obesity compared to Ixekizumab alone.
This study provides crucial real-world evidence highlighting the differential risk of ketoacidosis between semaglutide and tirzepatide in non-diabetic patients using these drugs for obesity. **Clinicians should be hig…
This study reinforces **tirzepatide's** efficacy as a monotherapy for **type 2 diabetes**, particularly in early-stage disease and in a Chinese population. The substantial reductions in **HbA1c** (over **2%**) and bod…
This pragmatic trial design is crucial for understanding **tirzepatide**'s real-world effectiveness and long-term impact in a primary care setting, moving beyond highly controlled clinical trial environments. **The fi…
This real-world data highlights a significant and rapid shift in **PCOS** management, indicating that incretin-based therapies like **GLP-1 RAs** and **GIP/GLP-1 RAs** are increasingly being prescribed for weight and …
This ACP guideline provides a crucial, evidence-based roadmap for clinicians navigating the complex landscape of weight management. **It firmly establishes GLP-1 and GLP-1/GIP agonists as the primary pharmacologic too…
This systematic review provides critical, albeit moderately certain, insights for clinicians, patients, and healthcare systems navigating pharmacologic options for **overweight** and **obesity**. **Prioritize phenterm…
This meta-analysis clarifies that **GLP-1 RAs** are not a universal solution for all **heart failure** patients. While they offer significant improvements in **quality of life** and **functional capacity** for individ…
This analysis provides compelling evidence that **tirzepatide offers a significant pharmacotherapeutic option for primary CVD prevention in obese Japanese adults, extending beyond its known weight loss benefits.** The…
Tirzepatide significantly lowered HbA1c in 107 non-obese Japanese T2D patients over 6 months. BMI reduction was more pronounced in higher baseline BMI groups.
This study provides compelling real-world evidence that **sex is a significant predictor of tirzepatide efficacy**, with women demonstrating a more robust weight loss response than men. This finding suggests that pers…
**This review reinforces semaglutide's position as a cornerstone therapy for metabolic disorders, guiding clinicians and informed users on its optimal application and emerging benefits.** It highlights how **semagluti…
This study provides a critical, data-driven perspective on **GLP-1 RA** safety, particularly highlighting potential interactions with common herbal supplements. **Patients using GLP-1 RAs for obesity should exercise c…
A Phase 1/2a study evaluated the safety, tolerability, pharmacokinetics, pharmacodynamics, and body weight effects of **RN3161 (LY3841136)** as monotherapy and combined with **tirzepatide**.
**Anti-obesity pharmacotherapy** represents a significant advance in managing **obesity** and its comorbidities. While this abstract doesn't detail specific findings, understanding the impact of these agents on inflam…
If successful, this research could significantly broaden the perceived benefits of **semaglutide** and **tirzepatide** beyond weight loss and glycemic control, particularly for **postmenopausal women**. **Understandin…
**GLP-1 RAs are not currently approved or guideline-recommended for fertility restoration**, despite promising findings. This review highlights their potential to address underlying metabolic and hormonal dysfunctions…
GLP-1 RAs and dual GIP/GLP-1 agonists represent a potent therapeutic option for **pediatric obesity**, offering significant BMI reductions. **Clinicians should consider these agents for eligible children and adolescen…
This framework provides a crucial blueprint for clinicians and individuals using **GLP-1RA** or **dual incretin** therapies, offering actionable strategies to enhance treatment efficacy and tolerability. **Adopting a …
This review underscores an urgent need for robust policy enforcement and systemic changes to mitigate **alcohol-related harm** in Europe. **Implementing evidence-based alcohol policies, such as increased taxation, min…
These real-world findings reinforce that **tirzepatide offers a metabolically favorable weight loss profile, prioritizing fat reduction while relatively preserving lean muscle mass**. For individuals managing **obesit…
This innovative `TAPS-ASAL` method represents a significant leap forward in peptide manufacturing, offering a **scalable, sustainable, and cost-effective route** for producing complex therapeutic peptides. For the bio…
This study provides compelling, albeit hypothesis-generating, real-world evidence that **GLP-1-based therapies like semaglutide and tirzepatide may offer substantial protection against heart and respiratory failure in…
If successful, this trial could **revolutionize fertility-sparing treatment for endometrial cancer** by integrating a potent weight-loss medication directly into the therapeutic strategy. Current progestin-only approa…
If successful, this pilot trial could **redefine treatment strategies for individuals with co-occurring Alcohol Use Disorder and overweight/obesity**. Currently, therapeutic options that effectively address both condi…
**This study suggests a novel and potentially more effective therapeutic strategy for psoriatic arthritis patients who are also overweight or obese.** For clinicians and patients, this means that adding a **GLP-1R/GIP…
This study provides crucial `CGM`-based evidence supporting the use of **GLP-1 receptor agonists** or **GLP-1/GIP dual agonists** as adjunct therapy for insulin-treated **type 2 diabetes** patients fasting during Rama…
The emergence of effective pharmacological options for **Obstructive Sleep Apnea Syndrome (OSAS)** represents a critical advancement for patients struggling with compliance to traditional therapies like CPAP. **This r…
**Tirzepatide's potential to induce intestinal healing in Crohn's disease represents a significant shift from current inflammation-centric treatments.** If successful, this study could pave the way for a new therapeut…
This systematic review provides crucial validation for the use of incretin-based therapies and `SGLT2` inhibitors in managing **MASH**, marking a significant shift in treatment paradigms. **Clinicians now have robust …
This analysis highlights a critical, unaddressed public health challenge: the increasing exposure of reproductive-aged women to **GLP-1 RAs** and the unknown impact on pregnancy outcomes. **Clinicians must prioritize …
Disproportionality analysis of FAERS data indicates a significant association between GLP-1 RAs and alopecia reporting, warranting further investigation.
This case report suggests that **rapid weight loss induced by GLP-1 RAs like tirzepatide might be a contributing factor to peripheral neuropathies such as brachial plexopathy**. For clinicians and individuals undergoi…
**Integrating metabolic therapies with anti-inflammatory biologics could revolutionize treatment for PsA patients with obesity.** This research suggests a critical shift towards precision medicine, where a patient's m…
This study offers a crucial step towards optimizing weight loss therapies by addressing the often-overlooked challenge of lean mass preservation. **Combining tirzepatide with a myostatin inhibitor like apitegromab cou…
**Tirzepatide** is being evaluated for maintaining weight reduction in adults with obesity or overweight and comorbidities in a randomized, double-blind trial.
This first-in-human study of ARO-ALK7 marks a significant step towards potentially introducing a novel mechanism for **obesity** and **Type 2 Diabetes Mellitus** treatment. If successful, `ALK7` inhibition could offer…
This study provides crucial real-world safety data, indicating that the risk of **optic ischaemic neuropathy** is not a uniform class effect across all incretin-based therapies. **Clinicians and patients using semaglu…
The landscape for **Obstructive Sleep Apnea (OSA)** management is undergoing a significant transformation, moving beyond symptomatic treatment with CPAP to address the underlying **obesity** and metabolic drivers. **C…
This review solidifies the role of GLP-1RAs as a cornerstone therapy for patients with **MASLD**, especially those with co-existing obesity, type 2 diabetes, advanced fibrosis, or heart failure. The dual benefit of im…
This study demonstrates that integrating a virtual behavioral program with **semaglutide/tirzepatide** via telemedicine can lead to substantial improvements in psychosocial well-being for individuals with obesity. **F…
This review reaffirms that **dulaglutide** remains a valuable option in cardiometabolic care, not superseded but rather complementary to newer agents. For clinicians and patients, this means **dulaglutide** offers a p…
This systematic review provides compelling evidence that GLP-1RAs extend their therapeutic utility beyond metabolic disorders to significantly improve outcomes in **respiratory diseases**. For individuals with **obstr…
If successful, this study could significantly expand the therapeutic utility of **Tirzepatide** beyond **Type 2 Diabetes**. For individuals with **Type 1 Diabetes** struggling with **insulin resistance** and weight ga…
**Ensuring consistent drug delivery across various injection devices is crucial for the widespread adoption and patient safety of tirzepatide.** If the study confirms pharmacokinetic and safety similarity, it provides…
Two new studies will evaluate the feasibility and value of incorporating individualized diabetes risk prediction models into primary care for people with prediabetes.
**For individuals discontinuing GLP-1 RA therapy, this review highlights the urgent need for structured, evidence-based protocols to prevent weight regain.** Clinicians currently lack clear guidance on how to support …
Leading medical societies issued a joint advisory detailing nutritional strategies to support GLP-1 receptor agonist therapy for obesity and improve patient outcomes.
Research investigates the impact of long-acting incretin-based therapies like **semaglutide** and **tirzepatide**, delivered via telemedicine, on psychosocial outcomes in obesity management.
This study provides compelling evidence that **GLP-1RAs** may offer a significant **chemopreventive benefit** against **obesity-associated cancers** in obese, nondiabetic individuals, extending their utility beyond we…
Free, no account — handy when you're working with Tirzepatide.